Alyeska Investment Group L.P. Trims Position in Insmed, Inc. $INSM

Key Points

• Alyeska Investment Group L.P. reduced its shareholding in Insmed, Inc. by 21.5%, selling 200,779 shares in the first quarter, leaving it with approximately 735,000 shares valued at $56 million.
• A number of institutional investors, including Cullen Frost Bankers and Versant Capital Management, have significantly increased their stakes in Insmed during the same period, indicating renewed interest in the biopharmaceutical company.
• Insmed reported a quarterly loss of ($1.70) earnings per share, missing analyst estimates, though revenues grew 18.9% year-over-year to $107.42 million.

Alyeska Investment Group L.P. decreased its position in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 21.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 735,000 shares of the biopharmaceutical company's stock after selling 200,779 shares during the quarter. Alyeska Investment Group L.P. owned 0.40% of Insmed worth $56,073,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of INSM. AQR Capital Management LLC boosted its stake in shares of Insmed by 2.1% during the 4th quarter. AQR Capital Management LLC now owns 64,171 shares of the biopharmaceutical company's stock worth $4,430,000 after acquiring an additional 1,291 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Insmed during the 4th quarter worth approximately $227,000. Baird Financial Group Inc. purchased a new stake in shares of Insmed during the 4th quarter worth approximately $1,539,000. Cetera Investment Advisers boosted its stake in shares of Insmed by 15.0% during the 4th quarter. Cetera Investment Advisers now owns 10,154 shares of the biopharmaceutical company's stock worth $701,000 after acquiring an additional 1,321 shares in the last quarter. Finally, Duquesne Family Office LLC boosted its stake in shares of Insmed by 2,867.4% during the 4th quarter. Duquesne Family Office LLC now owns 593,470 shares of the biopharmaceutical company's stock worth $40,973,000 after acquiring an additional 573,470 shares in the last quarter.

Insider Activity at Insmed

In other Insmed news, CFO Sara Bonstein sold 58,400 shares of the stock in a transaction on Monday, July 21st. The stock was sold at an average price of $102.67, for a total transaction of $5,995,928.00. Following the transaction, the chief financial officer owned 73,505 shares of the company's stock, valued at $7,546,758.35. This represents a 44.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO William Lewis sold 129,805 shares of the stock in a transaction on Monday, June 16th. The stock was sold at an average price of $100.39, for a total value of $13,031,123.95. Following the transaction, the chief executive officer directly owned 233,924 shares in the company, valued at approximately $23,483,630.36. This represents a 35.69% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 477,554 shares of company stock worth $49,433,687. Company insiders own 3.00% of the company's stock.

Analyst Ratings Changes

INSM has been the topic of several research analyst reports. UBS Group boosted their price target on Insmed from $124.00 to $133.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. William Blair assumed coverage on Insmed in a research note on Wednesday, August 20th. They issued an "outperform" rating on the stock. Stifel Nicolaus upped their target price on Insmed from $121.00 to $145.00 and gave the company a "buy" rating in a research note on Thursday, August 14th. Wells Fargo & Company upped their target price on Insmed from $140.00 to $171.00 and gave the company an "overweight" rating in a research note on Wednesday, September 3rd. Finally, Royal Bank Of Canada upped their target price on Insmed from $108.00 to $120.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Sixteen analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Insmed presently has a consensus rating of "Moderate Buy" and a consensus target price of $139.86.

Insmed Price Performance

INSM stock traded up $0.13 on Tuesday, reaching $146.81. The company had a trading volume of 521,740 shares, compared to its average volume of 2,783,015. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $147.51. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. The company's fifty day moving average is $115.56 and its 200 day moving average is $90.20. The company has a market cap of $31.03 billion, a P/E ratio of -25.71 and a beta of 0.96.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. During the same quarter last year, the firm posted ($1.94) earnings per share. The company's revenue was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. On average, research analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.